• Sponsored Content

BPI Staff

July 18, 2019

1 Min Read

2019-BIO-Theater-Lonza-Ibex-300x155.pngDuring a BPI Theater at BIO presentation on Wednesday, 5 June 2019, Charles Christy, director of commercial development at Ibex Solutions (Lonza Pharma and Biotech), considered the increasing speed of molecule discovery, process development, and clinical approval in the biopharmaceuticals industry. Weighing the promises and pitfalls of such a volatile, uncertain market, Christy offered drug developers advice about when to build biomanufacturing facilities in-house and when to outsource services. One solution, Christy suggests, is to partner with agile contract development manufacturing organizations (CDMOs) that can repurpose failed molecules and resources, enabling sponsor firms to turn risks into potential rewards.

You May Also Like